Deep Response in Multiple Myeloma: A Critical Review

Deep Response in Multiple Myeloma: A Critical Review

Novel and more effective treatment strategies against multiple myeloma (MM) have significantly prolonged patients’ survival and raised interest in the depth of response and its association with clinical outcome. Minimal residual disease (MRD) has emerged as one of the most relevant prognostic factor...

Full description

Bibliographic Details
Main Authors:	Mariateresa Fulciniti, Nikhil C. Munshi, Joaquin Martinez-Lopez
Format:	Article
Language:	English
Published:	Hindawi Limited 2015-01-01
Series:	BioMed Research International
Online Access:	http://dx.doi.org/10.1155/2015/832049

Similar Items

Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation
by: Arif E. Cetin, et al.
Published: (2017-11-01)

Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma
by: Yanira Ruiz-Heredia, et al.
Published: (2021-06-01)

Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma
by: Mariateresa Fulciniti, et al.
Published: (2018-12-01)

Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma
by: Fulciniti, Mariateresa, et al.
Published: (2020)

Biological Insights into Myeloma and Other B Cell Malignancies
by: Mariateresa Fulciniti, et al.
Published: (2016-01-01)

Genomic patterns of progression in smoldering multiple myeloma
by: Niccolò Bolli, et al.
Published: (2018-08-01)

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
by: Mehmet Kemal Samur, et al.
Published: (2021-02-01)

THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT
by: Anuj Mahindra, et al.
Published: (2010-05-01)

THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT
by: Paul Richardson, et al.
Published: (2010-05-01)

Genomic landscape and chronological reconstruction of driver events in multiple myeloma
by: Francesco Maura, et al.
Published: (2019-08-01)

Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device
by: Menachery, Anoop, et al.
Published: (2017)

The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression
by: Almudena García-Ortiz, et al.
Published: (2021-01-01)

Timing the initiation of multiple myeloma
by: Even H. Rustad, et al.
Published: (2020-04-01)

Response to pneumococcal vaccination in multiple myeloma
by: Loïc Renaud, et al.
Published: (2019-07-01)

Classify hyperdiploidy status of multiple myeloma patients using gene expression profiles.
by: Yingxiang Li, et al.
Published: (2013-01-01)

Risk and Response-Adapted Treatment in Multiple Myeloma
by: Titouan Cazaubiel, et al.
Published: (2020-11-01)

Multiple Myeloma
Published: (2021)

Multiple myeloma
by: Larisa P. Mendeleeva, et al.
Published: (2021-02-01)

Review of Venetoclax in CLL, AML and Multiple Myeloma
by: Masa Lasica, et al.
Published: (2021-05-01)

Elotuzumab for Treatment of Multiple Myeloma (Literature Review)
by: OM Votyakova
Published: (2016-10-01)

Logic programming reveals alteration of key transcription factors in multiple myeloma
by: Bertrand Miannay, et al.
Published: (2017-08-01)

Droplet Microfluidics for the ex Vivo Expansion of Human Primary Multiple Myeloma Cells
by: Pilar Carreras, et al.
Published: (2020-02-01)

Multiple Myeloma Masquerading as Ovarian Carcinosarcoma Metastases: A Case Report and Review of the Approach to Multiple Myeloma Screening and Diagnosis
by: Robert Stuver, et al.
Published: (2018-01-01)

Multiple myeloma and cardiovascular risk (a literature review)
by: B. B. Samura, et al.
Published: (2020-11-01)

Dysregulated APOBEC3G causes DNA damage and promotes genomic instability in multiple myeloma
by: Srikanth Talluri, et al.
Published: (2021-10-01)

Multiple Myeloma An Overview
Published: (2012)

Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma
by: Konstantinos Papadimitriou, et al.
Published: (2020-11-01)

Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma
by: Efrat Markus, et al.
Published: (2020-05-01)

Modulation of Notch in an Animal Model of Multiple Sclerosis
by: Munshi, Manit Nikhil
Published: (2016)

Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma
by: Accardi, F., et al.
Published: (2022)

Living With Multiple Myeloma
by: Leanne Monterosso PhD, BNurs(Hons), GCert Tert Teach, RN, RM, NNT, FACN, et al.
Published: (2018-03-01)

The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma
by: Yuji Mishima, et al.
Published: (2017-04-01)

Smoldering Multiple Myeloma
by: Minjie Gao, et al.
Published: (2015-01-01)

Hematuria in Multiple Myeloma
by: Ali Akbar Handjani, et al.
Published: (1965-01-01)

Immunotherapy in Multiple Myeloma
by: Cinnie Yentia Soekojo, et al.
Published: (2020-03-01)

Progress in multiple myeloma
by: Reinhold Munker, et al.
Published: (2019-01-01)

Hematuria in Multiple Myeloma
by: Ali Akbar Handjani, et al.
Published: (1965-12-01)

Integrins in multiple myeloma
by: Naoki Hosen
Published: (2020-03-01)

Multiple Myeloma: An Update
by: Khalil Al-Farsi
Published: (2013-01-01)

Immunotherapy for Multiple Myeloma
by: Nicolaus Kröger, et al.
Published: (2012-01-01)